Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need

Myelodysplastic Syndromes

(2017)   Journal of the National Comprehensive Cancer Network

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

Economic Analysis of Decitabine Versus Best Supportive Care in the Treatment of Intermediate- and High-Risk Myelodysplastic Syndromes From a US Payer Perspective

(2011) Feng Pan et al.   CLINICAL THERAPEUTICS

Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support

(2010) Arturo Pereira et al.   AMERICAN JOURNAL OF HEMATOLOGY

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Estimation of economic costs associated with transfusion dependence in adults with MDS

(2009) Jennifer R. Frytak et al.   CURRENT MEDICAL RESEARCH AND OPINION

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD